A food-use safety claim is not approval of an injectable medicine. The distinction is important when AOD-9604 is described online as FDA approved, FDA deemed safe or generally recognized as safe without specifying the actual decision.
GRAS has a defined context
The FDA's GRAS guidance concerns substances used in human or animal food. It does not establish a therapeutic indication or validate injection of a research preparation.
This article does not authenticate a particular AOD-9604 GRAS claim. Even a valid conclusion for specified food use would not answer a different route, formulation or medical-treatment question.
The words safe and approved should not be detached from their object and conditions.
Compounding records are another separate process
At the October 1, 2026 check, AOD-9604 appeared in the withdrawn-nomination section of the FDA's bulk-substance safety page. It should not be casually described using an outdated table category.
The 2024 FDA briefing is a scientific assessment prepared for an advisory process. It is not itself a finished-product approval or a blanket legal ruling about every clinical circumstance.
Check the exact regulatory statement
A useful status claim identifies the country, substance or product, decision and date. A screenshot, vendor statement or Reddit reply is not enough to establish all four.
For a Canadian audience, United States food or compounding terminology does not establish authorization in Canada. Current jurisdiction-specific review is necessary before commercial publication.
The clinical evidence and product-quality questions also remain even when the regulatory language is correctly stated. A status label cannot supply missing efficacy data or authenticate a container.
The conclusion is narrow but important: do not use a GRAS statement as reassurance that an AOD-9604 injection is approved, effective or suitable. Those are different claims requiring different evidence.